Santa Sp. z o.o. sp.k.

Kielce 13 trials 4 recruiting

13 Registered trials

4 Currently recruiting

Organisation

Santa Sp. z o.o. sp.k.

Location

Kielce, Poland

Identifier

ORG-100040857

Address

Ul. Zagorska 20/26, 25-355, Poland

Departments

ETG Kielce
ETG Kielce Ul. Zagórska 20/26 25-355, Kielce, Poland
Gastroenterology
n/a
Polimedica PTG Kielce
Santa sp. Z o.o. sp. K Polimedica PTG Kielce Ul. Zagórska 20/26 25-355, Kielce, Poland

Clinical trials at this site (13)

Search interface

ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Not authorised

2022-500536-11-00 Moderately to severely active ulcerative colitis 5
ABTECT-Maintenance – ABX464 Treatment Evaluation for ulcerative Colitis Therapy Not authorised

2022-500537-84-00 Moderately to severely active ulcerative colitis 5
Randomised efficacy and safety clinical trial of PQ Birch in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by … Pending

2023-507427-28-00 seasonal allergic rhinitis and/or rhinoconjunctivitis 5
BETRI-Prospective: Asthma control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 µg]) vs Single Inhaler ICS/LABA (200/… Pending

2025-524289-56-00 Asthma 6
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting

2023-508234-34-00 Crohn's disease 4 2025-01-27
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis Recruiting

2023-508817-18-00 Perennial Allergic Rhinitis (PAR) 5 2024-10-08
Long-term clinical trial of PQ Grass in paediatric subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass poll… Recruiting

2023-508520-36-00 Seasonal allergic rhinitis/rhinoconjunctivitis induced 5 2024-09-06
Allopurinol as a preventive drug in patients with high and very high cardiovascular risk, taking into account the presence of the long-COVID… Recruiting

2024-517610-15-00 hyperuricemia, hypertension, ischemic stroke, intracere 5 2024-03-28
A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis. Ended

2023-507705-34-00 Moderate to Severe Active Ulcerative Colitis 5 2025-08-29
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis Ended

2023-506655-19-00 Ulcerative Colitis (UC) 4 2024-05-16
ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Ended

2022-500536-11-01 Moderately to severely active ulcerative colitis 5 2023-06-08
A study of GSK3511294 (Depemokimab) in participants who were previously enrolled in 206713 or 213744; Open-Label Extension Ended

2023-505203-23-01 Severe asthma with an eosinophilic phenotype 5 2021-07-26
Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease Ended

2024-511553-22-00 Moderately to Severely Active Crohn's Disease 5 2018-10-05